Ergomed (LON:ERGO) Given “Buy” Rating at Numis Securities

Ergomed (LON:ERGO)‘s stock had its “buy” rating restated by equities research analysts at Numis Securities in a report issued on Thursday, ThisIsMoney.Co.Uk reports.

Shares of ERGO opened at GBX 266 ($3.48) on Thursday. The stock has a market cap of $123.80 million and a price-to-earnings ratio of -13.30. Ergomed has a 12 month low of GBX 145 ($1.89) and a 12 month high of GBX 258 ($3.37). The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.41 and a current ratio of 1.48.

In related news, insider Jan Petracek bought 79,405 shares of the business’s stock in a transaction on Tuesday, April 16th. The shares were purchased at an average cost of GBX 153 ($2.00) per share, with a total value of £121,489.65 ($158,747.75). Also, insider Richard Barfield bought 36,000 shares of the business’s stock in a transaction on Friday, June 7th. The shares were bought at an average cost of GBX 241 ($3.15) per share, for a total transaction of £86,760 ($113,367.31).



About Ergomed

Ergomed plc provides clinical research, and drug development and safety and medical information services in the United Kingdom and internationally. The company offers clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies.

See Also: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Receive News & Ratings for Ergomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed and related companies with MarketBeat.com's FREE daily email newsletter.